StageZero Life Sciences (TSXV:SZLS.H) Short Percentage of Float


TSXV:SZLS.H StageZero Life Sciences Ltd TSXV:SZLS.H
10 GF Score
Price C$0.04
View Full Analysis

What is StageZero Life Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TSXV:SZLS.H vs IDTA, TTOO, NSTM: Short Percentage of Float Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences Short Percentage of Float vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Short Percentage of Float falls into.


TSXV:SZLS.H
10GF Score
StageZero Life Sciences Ltd TSXV:SZLS.H
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for TSXV:SZLS.H

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.04
Price